戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 emotherapy (cyclophosphamide, cisplatin, and carmustine).
2 godendrogliomas treated with temozolomide or carmustine.
3  doxorubicin, dactinomycin, dacarbazine, and carmustine.
4 y high-dose cyclophosphamide, cisplatin, and carmustine.
5  agents such as procarbazine, lomustine, and carmustine.
6     High drug concentrations (0.5-3.5 mM for carmustine, 0.3-0.4 mM for 4-HC, and 0.2-1.0 mM for pacl
7  animals and 26 days in animals treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea 20 mg/k
8 ined from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCN
9 , mitoxantrone, chlorambucil, melphalan, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)]
10    The failure of alkylating agents, such as carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea; BCNU],
11 e (3.3, 1.0-10.2); for lung transplantation, carmustine (12.3, 3.1-48.9) and mean lung radiation of g
12 g/m(2) and cisplatin 25 mg/m(2) days 1 to 3, carmustine 150 mg/m(2) day 1 every other cycle, and tamo
13 ) on days 1 through 3 and 22 through 24 plus carmustine (150 mg/m2) on day 1.
14 polymer implant; significant (0.4 microM for carmustine, 3 microM for 4-HC, and 0.6 microM for paclit
15 and therapeutic dose of 0.75 Gy on day -12), carmustine 300 mg/m(2) (day -6), etoposide 100 mg/m(2) t
16              Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) o
17                                   Either [3H]carmustine, 4-hydroperoxycyclophosphamide (4-HC), or pac
18 ous HCT-ASCT (rituximab 375 mg/m(2) [day 1], carmustine 400 mg/m(2) [day 2], thiotepa 2 x 5 mg/kg [da
19 and carmustine-thiotepa and autologous HSCT (carmustine 400 mg/m(2) in 500 mL glucose 5% solution in
20 D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m(2) on day -6, and thiotepa 5 mg/kg e
21 us gene-modified HSCs following single-agent carmustine administration.
22  fractionation total lymphoid irradiation or carmustine and ASCT.
23 phamide and either total body irradiation or carmustine and autografting (median follow-up, 3.6 years
24 th the alkylating agents temozolomide (TMZ), carmustine and chlorambucil.
25                                      Topical carmustine and intravenous O6-benzylguanine.
26 anine (O(6)BG) and nitrosourea drugs such as carmustine and methylating agents such as temozolomide.
27 onses and 8 partial responses to combination carmustine and O6-benzylguanine treatment.
28 num treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) plus autologous hematopo
29 n most frequently used was cyclophosphamide, carmustine, and etoposide (n = 47).
30 e Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor respon
31 ne O(6)-targeting drugs such as cloretazine, carmustine, and temozolomide and that (ii) AGT levels in
32                         The MTD was 20 mg of carmustine applied once in combination with 2 daily dose
33 c analysis indicated that tissue exposure to carmustine area under concentration-time curve achieved
34 tiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently w
35 ain tumors was correlated with resistance to carmustine (BCNU) chemotherapy.
36 tivity of the combination of thalidomide and carmustine (BCNU) in patients with recurrent high-grade
37              We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity an
38             We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltr
39 of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progressio
40 etermine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable
41                            Local delivery of carmustine (BCNU) via biodegradable polymers prolongs su
42 novel core-sheath fiber loaded with the drug carmustine (BCNU) was evaluated in an in vivo brain tumo
43 h high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) with AHPCS.
44 d high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) with PBPC support.
45 entiated cells exposed to sublethal doses of carmustine (BCNU), a classic alkylating chemotherapeutic
46 adiation (TBI) (67 patients) or an augmented carmustine (BCNU), cyclophosphamide, and etoposide (BCV)
47                           The combination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP),
48 d in 81 patients following chemotherapy with carmustine (BCNU), etoposide, cytarabine, and melphalan
49  form O(6)-alkylguanine DNA adducts, such as carmustine (BCNU), temozolomide, streptozotocin, and dac
50 rease in the LD(50) for DNA-alkylating agent carmustine (BCNU), which is commonly used to treat gliom
51  regimen was cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (
52 three patients), or thiotepa, etoposide, and carmustine (BCNU; one patient).
53 in those patients treated with chemotherapy [carmustine [BCNU], vincristine, flourouracil, and strept
54 determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly be
55 atumoural transport, including fluorouracil, carmustine, cisplatin, methotrexate, doxorubicin and pac
56 gents, including fluorouracil, temozolomide, carmustine, cisplatin, methotrexate, doxorubicin, and pa
57 90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM)
58 tuximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemoth
59 her overall response rates and reduced total carmustine doses but was associated with more cutaneous
60 mpared with single-dose O6-benzylguanine and carmustine, dual-dose O6-benzylguanine resulted in highe
61 (5-FU) or 5-FU + leucovorin, doxorubicin, or carmustine] enhance the antitumor effects, compared to 1
62  disease in patients who underwent high-dose carmustine, etoposide, and cyclophosphamide chemotherapy
63         Patients then received high doses of carmustine, etoposide, and cyclophosphamide followed by
64                        All patients received carmustine, etoposide, cytarabine, and cyclophosphamide
65 rastim-mobilized PBPCT versus ABMT following carmustine, etoposide, cytarabine, and melphalan (BEAM)
66 dL without transfusion for 5 days) following carmustine, etoposide, cytarabine, and melphalan (BEAM)
67                 Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and rec
68 pants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well
69 maging then received high-dose therapy using carmustine, etoposide, cytarabine, and melphalan with au
70         Patients underwent AHSCT using BEAM (carmustine, etoposide, cytarabine, melphalan)+antithymoc
71 ntation using BEAM-alemtuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan,
72 rmediate risk) received autologous SCT after carmustine-etoposide-cytarabine-melphalan.
73 l, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA throu
74 r high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support or intermedia
75 ediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support but without stem
76 ed with the drug sensitivity of oxaliplatin, carmustine, ifosfamide, imexon, lomustine, and BN-2629,
77      To determine whether dose escalation of carmustine in combination with dual-dose O6-benzylguanin
78 splatin-, nitrogen mustard-, mitomycin-, and carmustine-induced DNA adducts in S. cerevisiae are proc
79 s with prior radiotherapy received 450 mg/m2 carmustine instead of TBI.
80  1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, Carmustine) into biodegradable polymer poly(lactic-co-gl
81                   HCT-ASCT with thiotepa and carmustine is an effective treatment option in young pat
82 and prednisone (52 patients) or vincristine, carmustine, melphalan, cyclophosphamide, and prednisone
83 he response criteria: 15 in the vincristine, carmustine, melphalan, cyclophosphamide, and prednisone
84 EM trials: GEM2000 [VBMCP/VBAD (vincristine, carmustine, melphalan, cyclophosphamide, prednisone/vinc
85 status (P =.03), and cisplatin, carboplatin, carmustine or lomustine administration (P =.0002).
86 MF type, to evaluate treatment using topical carmustine plus 2 subsequent daily doses of intravenous
87 elapse-related mortality was increased after carmustine (RR = 2.3) and with use of peripheral blood s
88 gimen, with cyclophosphamide, cisplatin, and carmustine (STAMP-I), followed by autologous stem-cell t
89 years and were naive to prior use of topical carmustine therapy.
90 mL in a 1 h intravenous infusion, day 2) and carmustine-thiotepa and autologous HSCT (carmustine 400
91 from the last induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/
92 reening assay, diffusion of temozolomide and carmustine to hydrogel-encapsulated U87 cells from the p
93                          Nitrosoureas of the carmustine type inhibit only the NADPH reduced form of h
94               Additionally, i.c. delivery of carmustine via biodegradable polymers has been shown to
95 e optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics
96 coadministered with intracranially implanted carmustine wafers, without added toxicity.
97 r 14 days after surgical implantation of the carmustine wafers.
98  The MTD for dual-dose O6-benzylguanine plus carmustine was also ascertained.
99 to receive HDC (cyclophosphamide, cisplatin, carmustine), with autologous bone marrow rescue immediat